Clinical Trial Update: Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on adjuvant therapy with adebrelimab and apatinib for hepatocellular carcinoma at high risk of recurrence after curative resection…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: RECRUITING